In this article, we will take a detailed look at 12 Penny Stocks with Insider Buying in 2025.
Insider trading can be a reliable signal for gauging the degree of confidence that management has in the future of their company. This practice has been supported for decades by leading investors and analysts, who claim that there is only one reason for insiders to buy shares of their own companies – if they strongly believe the share prices are going to rise significantly. We discussed the theory behind insider buying in one of our recent articles named 10 Large-Cap Stocks with Insider Buying in 2025.
Insider buying can be an even more significant signal in the case of penny stocks, which are usually small- or micro-cap companies, because these stocks are often underfollowed or not followed at all, leading to significant price inefficiencies and overreactions from investors. This, in turn, may create pockets of opportunity that insiders exploit by leveraging their confidential information and visibility. Furthermore, given the smaller market cap, insiders can exert significant upward pressure on the stock price, which may help boost morale among shareholders.
READ ALSO: 10 Technology Stocks with Insider Buying in 2024
Empirical studies suggest that small caps tend to underperform relative to large caps during tough economic conditions, such as slowing GDP growth, inflation, high interest rates, and other exogenous pressures. Many believe that the US has already entered a new regime, called “Trump 2.0,” which will be dominated by higher inflation, lower economic support from government spending, and reduced availability of cheap labor, among several other possible challenges. Some surveys have hinted at a deteriorating business outlook among small- and mid-sized businesses, marked by lower CapEx budgets. Yardeni Research charts show that small-cap forward earnings have lagged significantly behind large caps since 2023. On top of that, the new economic regime in the US could further exacerbate these discrepancies and lead to greater relative underperformance of small caps, including penny stocks.
While the aforementioned developments could be bad for existing penny stock investors, they could also create investment opportunities for new investors. As the US broad market is still trading near its all-time highs, it has become increasingly difficult to find undervalued or even fairly valued large- and mid-cap companies. In such an environment, investors seeking higher returns may turn to smaller, lesser-known stocks with strong growth potential. The key takeaway for investors is that penny stocks could offer much more attractive, high-upside opportunities than large caps, and watching insider buying signals provides further reassurance regarding stock picking. Given this, we will take a look at some of the best penny stocks with insider buying.
A closeup of investor hands holding a small-cap investment security.
Our Methodology
We used Insider Monkey’s insider trading stock screener to find penny stocks trading under $5.00 share price with at least two insiders buying shares worth at least $100,000 in the last six months. We believe that multiple insiders buying significant amounts of stock represents a higher chance that insiders have high confidence in the company. For all the companies, we also include the number of hedge funds holding stakes in them, tracked by Insider Monkey as of Q4 2024. The stocks are ranked according to hedge fund positions.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
12. 374Water Inc. (NASDAQ:SCWO)
Number of Hedge Fund Holders: 1
374Water Inc. (NASDAQ:SCWO) is a US-based cleantech company specializing in innovative waste and wastewater treatment solutions. Founded in 2018, the company has developed the patented AirSCWO™ technology, which stands for Air Supercritical Water Oxidation. This process effectively treats both hazardous and non-hazardous organic waste streams by oxidizing contaminants at high temperatures and pressures, resulting in safe, dischargeable water, mineral byproducts, vent gas, and recoverable heat energy. The technology has undergone extensive testing at bench, pilot, and commercial scales, demonstrating enhanced performance and safety. By transforming waste into minimal impact, value-added products, SCWO aims to support a circular economy and assist businesses and local governments in achieving their Sustainable Development Goals.
374Water Inc. (NASDAQ:SCWO)’s technology is positioned to address critical waste challenges with a solution that offers unmatched commercial efficacy and scale. The company has made substantial progress in commercializing its technology across both solid and liquid waste streams, building a robust backlog and pipeline of opportunities totaling more than $1.8 billion. The company’s AirSCWO system effectively processes solid waste that can be preprocessed into slurries for treatment, including wastewater sludges, biosolids, spent granular activated carbon, ion-exchange resins, and hard-to-degrade plastics, as well as liquid waste such as firefighting foam, industrial solvents, and foamate streams.
374Water Inc. (NASDAQ:SCWO) has also demonstrated significant success in AFFF destruction tests on their lab-scale system and commercial scale AS1 and AS6 systems, achieving 99.999% plus destruction results. The company operates in multiple market segments including the $120 billion US drinking water and municipal wastewater management market, the $15 billion US federal waste management market, and the $80 billion US industrial waste management market. The company is actively raising capital to expand operations and is pursuing near-term revenue opportunities across AirSCWO capital sales, emerging Destruction as a Service business model, destruction demonstrations, and lab tests. The significant insider purchasing in the last six months further reinforces the strong outlook and reinvestment opportunities of the company.
11. OncoCyte Corporation (NASDAQ:OCX)
Number of Hedge Fund Holders: 2
OncoCyte Corporation (NASDAQ:OCX) is a molecular diagnostics company focused on developing and commercializing non-invasive, liquid biopsy diagnostics for early cancer detection and monitoring. Their product portfolio includes a gene expression test that assesses the tumor microenvironment to predict responses to immunotherapies, and a blood-based tool for monitoring therapeutic efficacy in cancer patients. Additionally, OCX offers a clinical blood-based test for monitoring solid organ transplantation, and a research-use-only test in the same domain. The company collaborates with Bio-Rad Laboratories to develop and commercialize transplant monitoring products using their instruments and reagents.
OncoCyte Corporation (NASDAQ:OCX) is making significant progress in democratizing transplant testing, with their technology now being run on three continents. The company has successfully signed agreements with leading transplant centers, including a top 5 transplant center in the United States and Germany. OCX is actively engaging with more than 30 high-volume transplant sites and expects to meet or exceed their goal of having 20 sites signed by the end of next year. Each site is projected to generate approximately $1 million per year in high-margin recurring clinical test kit revenue.
OncoCyte Corporation (NASDAQ:OCX) is also advancing its FDA program, with their first FDA meeting scheduled for early December to discuss validation plans. Their GraftAssure RUO kit test is exceeding expectations in Europe, and they are establishing potential meaningful market share in the US. The company recently raised $10.2 million in gross proceeds through a private placement, with support from existing investors including Bio-Rad. In oncology, their DetermaIO immune classifier continues to show promising results, with a peer-reviewed study validating its utility in identifying breast cancer patients most likely to benefit from atezolizumab. Given the aforementioned achievements, it is no surprise that at least two insiders bought more than $100,000 worth of company stock in the last six months.
10. CAMP4 THERAPEUTICS CORPORATION (NASDAQ:CAMP)
Number of Hedge Fund Holders: 4
CAMP4 Therapeutics Corporation (NASDAQ:CAMP) is a clinical-stage biopharmaceutical company focused on developing regulatory RNA-based therapies to address a wide range of genetic diseases. Its lead product candidate, CMP-CPS-001, is designed for the treatment of urea cycle disorders, while another program, CMP-SYNGAP, targets synaptic Ras GTPase activating protein 1-related disorders. In October 2024, CAMP successfully raised $75 million through its initial public offering, selling 6.82 million shares at $11 each. The company plans to use the IPO proceeds primarily for the clinical development of its product candidates.
CAMP4 Therapeutics Corporation (NASDAQ:CAMP) is pioneering a new class of RNA medicines focused on increasing targeted gene expression through their proprietary RAP Platform, which enables the discovery of novel regRNAs that regulate the expression of every protein-coding gene. The company’s lead metabolic program has demonstrated promising safety results in Phase 1 SAD studies, with no safety trends of concern and no treatment-emergent serious adverse events observed.
CAMP4 Therapeutics Corporation (NASDAQ:CAMP) is also targeting significant market opportunities, including approximately 5,000 UCD patients in the US, with 3,700 severe patients and over 1,200 symptomatic OTC female heterozygotes. In their CNS pipeline, CAMP is developing treatments for SYNGAP1-related disorders, which affect over 10,000 patients in the US, where there are currently no disease-modifying treatments available. The company has also expanded into Parkinson’s disease through their GBA1 program, targeting a substantial market of approximately 100,000 GBA-PD patients in the US out of approximately 1 million total PD patients. CAMP’s technology platform has demonstrated the ability to increase target gene expression in multiple preclinical studies, with their lead candidate showing up to a 40% increase in ureagenesis in non-human primates. With that being said, the company’s promising outlook is supported by significant insider buying in the last six months.
9. CalciMedica Inc. (NASDAQ:CALC)
Number of Hedge Fund Holders: 6
CalciMedica Inc. (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing first-in-class therapies for life-threatening inflammatory diseases with high unmet needs. Their proprietary technology targets the inhibition of calcium release-activated calcium channels, aiming to modulate immune responses and protect against tissue cell injury. The company’s lead product candidate is an intravenous formulation of a small molecule CRAC channel inhibitor, which is currently in development for the treatment of acute pancreatitis with systemic inflammatory response syndrome and asparaginase-associated pancreatitis. There are currently no approved disease-modifying treatments for these conditions. CALC’s approach offers potential therapeutic benefits in these life-threatening inflammatory diseases.
CalciMedica Inc. (NASDAQ:CALC) is developing novel CRAC channel inhibitors targeting life-threatening inflammatory diseases with high unmet medical needs. The company has demonstrated consistent positive clinical activity and good tolerability in multiple Phase 2 clinical trials in acute critical illnesses. CALC’s current cash runway extends into 1H26 and is expected to fund operations and completion of the ongoing KOURAGE Phase 2 trial in AKI patients. The market opportunity is substantial, with approximately 1 million target AKI population and around 100 thousand target AP population representing multi-billion US market opportunities with no approved therapies.
CalciMedica Inc. (NASDAQ:CALC) has strong intellectual property protection; their lead candidate, Auxora, has shown consistent reduction and prevention of acute respiratory failure and mortality across multiple clinical trials. In the CARPO Phase 2b trial, Auxora demonstrated positive impact on organ failure, particularly new onset severe respiratory failure, reduction of necrotizing pancreatitis, and reduction in time to medically indicated discharge and length of hospital stays. The drug has been well-tolerated in over 350 critically ill patients with no sudden unexpected serious adverse reactions reported to date. With a strong portfolio of promising pharmaceutical products, the company’s future appears bright, which is supported by significant insider purchasing in the last months.
8. GrowGeneration Corp. (NASDAQ:GRWG)
Number of Hedge Fund Holders: 6
GrowGeneration Corp. (NASDAQ:GRWG) is a leading specialty retailer of hydroponic and organic gardening products in the United States. The company operates over 30 retail and distribution centers across multiple states, with a product range encompassing nutrients, additives, growing media, advanced lighting technologies, and environmental control systems, catering to both commercial and home growers. Through their website, the company offers an extensive online superstore with over 10,000 products available for nationwide shipping. The company also provides turnkey facility designs, cultivation room designs, and on-site project consultations, aiming to enhance yields and reduce production costs for cultivators. GRWG is one of the best penny stocks with insider buying.
GrowGeneration Corp. (NASDAQ:GRWG) reported Q3 2024 net revenue of $50 million, slightly down from $53.5 million in Q2 2024, primarily due to planned store closures under their restructuring initiatives. The company achieved significant milestones, including the first positive same-store sales growth of 12.5% in three years. Proprietary brand sales increased to 23.8% of Cultivation and Gardening net sales, up from 19.4% last year, demonstrating progress toward their target of 35% by the end of 2025.
GrowGeneration Corp. (NASDAQ:GRWG) has completed its store rationalization plan, reducing its footprint from 65 stores to 31 operational locations. The company maintains a strong financial position with $55.2 million in cash and no debt as of September 30, 2024. It is also implementing a digital transformation strategy, including a B2B e-commerce portal launch in Q4, aimed at streamlining operations and enhancing customer experience. Management reiterated their full-year 2024 guidance for net revenue between $190 million to $195 million. The restructuring initiatives are expected to improve profitability and reduce expenses by a minimum of $12 million on an annualized basis, which may have positive effects on the stock price, as hinted by at least 2 insiders buying more than $100,000 worth of company stock in the last six months.
7. Custom Truck One Source Inc. (NYSE:CTOS)
Number of Hedge Fund Holders: 7
Custom Truck One Source Inc. (NYSE:CTOS) is a comprehensive provider of specialty equipment and services, catering to industries such as electric utility transmission and distribution, telecommunications, rail, forestry, and waste management. The company operates through three primary segments: Equipment Rental Solutions (ERS), Truck and Equipment Sales (TES), and Aftermarket Parts and Services (APS). The ERS segment offers rental services for new and used specialty equipment, including truck-mounted aerial lifts, cranes, service trucks, dump trucks, trailers, and digger derricks. The TES segment provides new equipment sales tailored to specific customer requirements across various end-markets. The APS segment delivers maintenance and repair services, alongside the rental and sale of specialized tools and aftermarket parts. With over 40 locations and a workforce exceeding 2,600 employees, CTOS positions itself as a “one-stop-shop” for specialty equipment needs, supporting the full lifecycle from acquisition to disposal. It is among the best penny stocks with insider buying.
Custom Truck One Source Inc. (NYSE:CTOS) owns a substantial rental fleet valued at $1.6 billion and a complementary sales business for new and used trucks. The company primarily serves four key markets: utility (60% of revenue), infrastructure (25%), rail and telecom (each approximately 5%), with a focus on serving major contractors like Quanta, MasTec, MYR Group, and Century. The company has demonstrated strong pricing power, having implemented price increases of 10% in 2022 and 6% in 2023, though maintaining stable pricing in 2024 due to market conditions. Recent performance shows positive momentum with OEC on rent increasing by $200 million in the quarter, with 70-80% of this growth coming from core business demand rather than storm-related work.
Looking forward, management anticipates double-digit EBITDA growth, driven by improved utilization rates returning to the mid-to-high 70s range, continued growth in both rental and sales segments, and potential benefits from lower floor plan interest expenses as inventory levels decrease. Custom Truck One Source Inc. (NYSE:CTOS) maintains a strategic focus on debt reduction with a target leverage ratio of 3.0x, while currently operating at 4.4x leverage. The optimistic guidance is further reinforced by significant insider purchases in the last six months.
6. Digital Turbine Inc. (NASDAQ:APPS)
Number of Hedge Fund Holders: 12
Digital Turbine Inc. (NASDAQ:APPS) is an independent mobile growth platform that provides end-to-end products and solutions for advertisers, publishers, carriers, and device OEMs. The company operates through two primary segments: On Device Solutions and App Growth Platform (AGP). The ODS segment includes Application Media, which delivers mobile applications to various publishers, carriers, OEMs, and devices, and Content Media, offering news, weather, sports, and other content, as well as programmatic advertising and media content delivery services. The AGP segment encompasses Advertising Solutions and Ad Monetization Solutions, enabling mobile app publishers and developers to monetize their active users through display, native, and video advertising. APPS’s services are utilized by mobile operators, OEMs, and other third parties, with operations spanning North America, South America, Germany, Singapore, India, Turkey, and Israel. APPS is one of the best penny stocks with insider buying.
Digital Turbine Inc. (NASDAQ:APPS) exceeded expectations in the latest Q3 2025 with revenue of $135 million, adjusted EBITDA of $22 million, and non-GAAP EPS of $0.13. The company demonstrated improved performance driven by increased advertising demand, transformation efforts showing bottom-line results, and enhanced execution, particularly in the On Device international business and brand strategy. The ODS segment reached $92 million in revenue, marking an 11% sequential increase, with record revenue per device achievements both domestically and internationally. The company’s international On Device revenues showed remarkable growth, up 100% year-over-year.
Digital Turbine Inc. (NASDAQ:APPS) is successfully executing its transformation program, having already achieved over $25 million in annualized cost efficiencies. The company is expanding its global device relationships through partnerships with Motorola, Nokia, ONE Store, Xiaomi, Telecom Italia Brasil, and T-Mobile in the US. Looking forward, the company provided guidance for fiscal year 2025 with projected revenue between $485 million to $490 million and non-GAAP adjusted EBITDA between $69 million and $71 million, which is further reinforced by at least two insiders buying more than $100,000 worth of APPS stock in the last six months.
5. United Homes Group Inc. (NASDAQ:UHG)
Number of Hedge Fund Holders: 14
United Homes Group Inc. (NASDAQ:UHG) is a homebuilding company that designs, builds, and sells homes in South Carolina, North Carolina, and Georgia. The company’s residential offerings include entry-level attached and detached homes, first-time move-up homes, and second move-up detached homes, catering to a diverse clientele. In January 2024, UHG expanded its operations by acquiring the homebuilding business and assets of Creekside Custom Homes, LLC, a home builder and land developer in South Carolina. This acquisition aligns with the company’s growth strategy and enhances its presence in the Southeast region. UHG ranks fifth on our list of the best penny stocks with insider buying.
United Homes Group Inc. (NASDAQ:UHG) is positioned as a builder of high quality, affordable houses with a focus on efficient, streamlined processes aimed at decreasing cycle times while improving inventory turnover rates and margins. The company demonstrated strong performance in the latest Q3 2024 with a 25% YoY increase in sales, 30% increase in total closings, and 35% increase in revenue. UHG maintains a strong lot position of approximately 8,600 lots, with ~99% of lots optioned, representing the highest percentage among its peer group.
United Homes Group Inc. (NASDAQ:UHG) operates with a land-light model, where lots are delivered “just in time,” enabling higher ROE. Since going public in 2023, UHG has completed three builder acquisitions, focusing on attaining scale through strategic acquisitions in high growth markets with strong lot pipelines and local market expertise. The company recently completed a refinancing transaction that reduced interest expense by ~320 bps, saving approximately $3.7 million annually, while also reducing leverage by $10.0 million from $80.0 million to $70.0 million. The potential arising from the aforementioned achievements is reinforced by strong insider purchasing in the last six months.
4. ModivCare Inc. (NASDAQ:MODV)
Number of Hedge Fund Holders: 15
ModivCare Inc. (NASDAQ:MODV) is a technology-enabled healthcare services company offering integrated supportive care solutions to public and private payors and their patients. The company’s value-based services address social determinants of health, enhance access to care, reduce costs, and improve outcomes. MODV is a leading provider of non-emergency medical transportation, personal care services, and remote patient monitoring. Additionally, the company holds a minority equity interest in Matrix Medical Network, which collaborates with health plans and providers nationwide to deliver a broad array of assessment and care management services aimed at improving health outcomes and financial performance.
ModivCare Inc. (NASDAQ:MODV) showed strong Q3 2024 results, driven by improvements in Personal Care Services, higher margins in Remote Patient Monitoring, and NEMT cost savings. The company has made significant progress in optimizing technology, automating contact center functions, and reducing NEMT unit costs through a multimodal network strategy. During the quarter, the company successfully collected $105 million in gross contract receivables, including $42 million from retrospective prepayment resets and $39 million from an early settlement with their largest MCO client. The company is transitioning many of its shared risk contracts to fee-for-service arrangements, which is expected to normalize working capital and free cash flow over the next 2-3 quarters.
Looking ahead, ModivCare Inc. (NASDAQ:MODV) expects 2025 adjusted EBITDA to increase approximately 10%, driven by membership growth, new contract wins, cost savings, and other strategic initiatives. However, the company faces headwinds in the Medicare Advantage space, with expectations of business contraction in 2025 as clients adjust their supplemental benefit spending. The company’s transformation across all segments has created a foundation for stability with technology, clinical capabilities, and customer engagement differentiations at scale, positioning it for sustainable growth. The optimistic outlook for the future is strengthened by at least two insiders purchasing more than $100,000 worth of MODV stock in the last six months.
3. Biodesix Inc. (NASDAQ:BDSX)
Number of Hedge Fund Holders: 18
Biodesix, Inc. (NASDAQ:BDSX) is a data-driven diagnostic solutions company specializing in lung disease. Utilizing an artificial intelligence-based platform, the company develops blood-based tests to address critical clinical questions. Their testing strategy assesses the risk of malignancy in pulmonary nodules, aiding physicians in determining appropriate patient management. For lung cancer patients, their proprietary strategy integrates several tests to support treatment decisions across all stages of the disease. BDSX also collaborates with biopharmaceutical companies, offering diagnostic research, clinical trial testing, and the development of companion diagnostics. The company leverages its proprietary AI platform to address complex diagnostic challenges in lung disease.
Biodesix, Inc. (NASDAQ:BDSX) delivered strong performance in the latest Q3 2024 with 35% YoY revenue growth, achieving $18.2 million in total revenue and maintaining robust gross margins of 77%. The lung diagnostic testing segment demonstrated significant growth with a 40% increase in revenue and 34% increase in test volumes compared to the prior year. The company expanded its coverage policies for Nodify XL2 test, adding new agreements with Blue Shield of California, Blue Cross Blue Shield Nebraska, Centene, Fallon and Security Health Plan in Wisconsin. Despite some temporary headwinds from hurricanes in the Southeast and slower sales team expansion, management reaffirmed their 2024 full-year revenue guidance of $70-72 million and maintained their expectation to achieve adjusted EBITDA breakeven in 2H 2025.
The biopharma services segment showed promising potential with contracted revenue not yet recognized increasing to $11.1 million from $8.1 million at the end of Q2 2024. Biodesix, Inc. (NASDAQ:BDSX) continues to strengthen its commercial presence, with plans to have 70-75 fully contributing sales team members by the end of 2024 and adding 6-8 sales team members per quarter throughout 2025. BDSX is advancing its clinical evidence generation through new studies, including the CLARIFY study which will evaluate outcomes in 4,000 patients who received Nodify testing. The strong potential of these advancements is supported by significant insider purchasing activity in the last six months.
2. Sunnova Energy International Inc. (NYSE:NOVA)
Number of Hedge Fund Holders: 19
Sunnova Energy International Inc. (NYSE:NOVA) is an energy services company specializing in residential solar and energy storage solutions. Collaborating with local dealers and contractors, NOVA offers services such as operations and maintenance, monitoring, repairs and replacements, equipment upgrades, and onsite power optimization. Their product portfolio includes add-on battery storage, home solar protection plans, new solar battery storage, and various other solar systems.
The recent Q4 2024 presented significant challenges for Sunnova Energy International Inc. (NYSE:NOVA), marked by peer distress, high interest rates, and regulatory uncertainties that made both consumers and capital providers more cautious. The company faced slowdowns in tax equity flow, which impacted capital deployment and resulted in 2024 cash generation falling below expectations. Despite these challenges, NOVA achieved notable operational improvements, including a 24% reduction in net service expense per customer over two years, while reducing total work orders by 12% and growing their cumulative solar customer base by over 70%.
Sunnova Energy International Inc. (NYSE:NOVA) has also taken strategic steps to strengthen its position, including prioritizing margin over growth, focusing on high-margin energy services, and implementing price increases to offset higher capital costs. Significant cost-cutting measures were implemented, including a 15% headcount reduction expected to contribute approximately $35 million towards total estimated annual cash savings of $70 million. In terms of financing, NOVA secured substantial asset-level funding in 2024, including $1.8 billion in solar asset securitizations and $1.3 billion in tax equity, marking the first year without issuing corporate level capital. Looking forward, the company is focusing on addressing its late 2026 corporate debt maturities by mid-2025, while maintaining its commitment to customer service quality. In the last six months, at least two insiders bought significant amounts of the company’s stock, which signals that NOVA’s struggles may be in the rear-view mirror.
1. Taboola.com Ltd. (NASDAQ:TBLA)
Number of Hedge Fund Holders: 28
Taboola.com Ltd. (NASDAQ:TBLA) is a technology company specializing in content recommendations across the open web. Leveraging an AI-based algorithmic engine, TBLA partners with digital properties, including websites, devices, and mobile apps, to suggest editorial content and advertisements to users. The company’s platform enables over 1.4 billion people to discover new and relevant content, enhancing user engagement and monetization opportunities for publishers. Advertisers utilize TBLA’s services to reach extensive audiences, driving conversions and business results.
Taboola.com Ltd. (NASDAQ:TBLA) achieved record financial performance in 2024, delivering gross profit of $667 million, representing 25% growth YoY, and adjusted EBITDA of $201 million, which more than doubled from the previous year. The company significantly exceeded its free cash flow target, generating $149 million, which was 49% above the original minimum target of $100 million. In a strategic shift, TBLA announced the launch of Realize, a new performance advertising platform aimed at expanding beyond native advertising to capture a $55 billion market opportunity in performance advertising.
For 2025, management is guiding for 2% gross profit and 2% adjusted EBITDA growth, maintaining a 30% EBITDA margin. To demonstrate confidence in its future, Taboola.com Ltd. (NASDAQ:TBLA) announced a $200 million expansion to its buyback authorization, bringing the total current authorization to approximately $240 million. The company’s strategy focuses on three main assets: unique first-party data reaching 600 million people daily, AI capabilities with 650 engineers, and unmatched supply partnerships with major publishers like NBC News, Disney, Yahoo, and Apple. The strong outlook is supported by at least two insiders buying more than $100,000 worth of company stock in the last six months.
Overall, Taboola.com Ltd. (NASDAQ:TBLA) ranks first on our list of the 12 penny stocks with insider buying in 2025. While we acknowledge the potential of TBLA as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than TBLA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
